Sartorius CellGenix GmbH
Bernd Leistler is an accomplished professional in the biochemistry and biotechnology sectors, currently serving as Vice President of Production at Sartorius CellGenix GmbH since December 2003. In this role, Bernd Leistler is a key member of the Management Team and an authorized signatory for the company, overseeing the process development and GMP-compliant manufacturing of recombinant cytokines and growth factors for cell and gene therapies. Previously, Bernd Leistler held the position of Director of Development & Production at Pharmacia Diagnostics GmbH & Co. KG, where leadership was provided to the Business Unit Autoimmunity and a team focused on diagnostic autoantigens. Early career experience includes a research fellowship at the University of Cambridge, exploring protein solubilization. Educational qualifications encompass a dissertation in Biophysical Chemistry from the Biocenter of the University of Basel and a diploma in Chemistry from Albert Ludwigs University of Freiburg.
This person is not in any teams
Sartorius CellGenix GmbH
Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as prorietary serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world. As an ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. Sartorius CellGenix is headquartered in Freiburg, Germany.